Clinical trials: Hypoactive Sexual Desire Disorder (HSDD)
Sexual Dysfunctions, Psychological
Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder
Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens
- Trial name
- NCT00601367
- Testing
- flibanserin flexible dose
- Where
- 68 sites in Austria, Belgium and 10 more
- Volunteers
- 480 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunctions, Psychological
Flibanserin Versus Placebo in Premenopausal Women With HSDD
To establish efficacy of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in 6-month treatment, vs placebo for Hypoactive Sexual Desire Disorder in premenopausal European women.
- Trial name
- NCT00491829
- Testing
- 50 mg qhs, 100 mg
- Where
- 86 sites in Austria, Belgium and 11 more
- Volunteers
- 945 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the…
- Trial name
- HSDD (NCT02333071)
- Testing
- Bremelanotide
- Where
- 91 sites in United States, Canada
- Volunteers
- 723 people
- Sponsor
- Palatin Technologies, Inc
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in surgically menopausal women who are taking estrogen therapy.
- Trial name
- NCT00331123
- Testing
- Testosterone Transdermal System
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 562 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder (HSDD), Low Libido
Acupuncture for Sexual Dysfunction
Female Sexual Dysfunction (FSD) affects up to 43% of women in the United States and Hypoactive Sexual Desire Disorder (HSDD) is the most common form. There is no standardized treatment for this condition.
- Conditions
- Hypoactive Sexual Desire Disorder (HSDD), Low Libido, Female Sexual Dysfunction (FSD)
- Trial name
- NCT02070029
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- TriHealth Inc.
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in surgically menopausal women who are taking estrogen therapy.
- Trial name
- NCT00331214
- Testing
- Testosterone Transdermal System
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 533 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder
An Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD
This is an unblinded study to be conducted at a single research center, San Diego Sexual Medicine. Eligible subjects will receive 50 mg capsules of Kyzatrax® to be taken orally daily over a 3-month period.
- Trial name
- NCT06082817
- Testing
- Oral Testosterone Undecanoate
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- San Diego Sexual Medicine
Hypoactive Sexual Desire Disorder
Lybrido for Female Sexual Dysfunction
The Lybrido study is a double-blind, randomized, placebo-controlled study with a 4-week baseline establishment period, 16 week treatment period and a follow up period for a total of 26 weeks on study.
- Trial name
- NCT01432665
- Testing
- Sildenafil, Testosterone
- Where
- 14 sites in United States
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Emotional Brain NY Inc.
Hypoactive Sexual Desire Disorder
Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy
Unblinded study of flibanserin for 8 weeks with responders randomized 1:1 to receive study medication alone vs. study medication and sex therapy for 12 additional weeks.
- Trial name
- NCT02714049
- Testing
- sex therapy, flibanserin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- San Diego Sexual Medicine
Sexual Dysfunctions, Psychological
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
This trial examines the way flibanserin is metabolized in postmenopausal women with Hypoactive Sexual Desire Disorder.
- Trial name
- NCT01188603
- Testing
- flibanserin 100 mg dose every evening
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder (HSDD)
Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in naturally menopausal women who are taking estrogen or estrogen/progestin therapy.
- Trial name
- NCT00349791
- Testing
- Testosterone Transdermal System
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 549 people
- Sponsor
- Warner Chilcott
Sexual Dysfunctions, Psychological
A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder
To generate additional long-term safety and efficacy data on flibanserin in premenopausal women and establish long-term safety and tolerability of flibanserin in naturally postmenopausal women with Hypoactive Sexual Desire…
- Trial name
- NCT01103362
- Testing
- flibanserin
- Where
- 95 sites in United States, Canada
- Volunteers
- 596 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
The objective of this study is to evaluate the persistence of benefit of LibiGel (testosterone gel) 300 mcg/day compared to placebo gel in a 12 week post-treatment period of Hypoactive Sexual Desire Disorder (HSDD) in surgically…
- Trial name
- NCT01235754
- Testing
- transdermal testosterone gel 1%
- Where
- 102 sites in United States, Canada
- Volunteers
- 626 people
- Sponsor
- BioSante Pharmaceuticals
Hypoactive Sexual Desire Disorder (HSDD)
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study
The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.
- Trial name
- NCT03619005
- Testing
- Prasterone 6.5 mg (0.50%) Vaginal Insert
- Where
- 10 sites in United States
- Sponsor
- EndoCeutics Inc.
Hypoactive Sexual Desire Disorder
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.
- Trial name
- NCT03287232
- Testing
- Prasterone 6.5 mg (0.50%) Vaginal Insert
- Where
- 69 sites in United States, Canada
- Volunteers
- 653 people
- Sponsor
- EndoCeutics Inc.
Sexual Dysfunctions, Psychological
A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).
To determine if long-term treatment with Flibanserin is safe and to monitor the effectiveness of Flibanserin in Women with HSDD that have already completed a previous study (511.70/71/.74/.75/.105) with Flibanserin.
- Trial name
- NCT00441558
- Testing
- Flibanserin
- Where
- 196 sites in United States, Canada
- Volunteers
- 1,723 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder
Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder
A double-blind, randomized, placebo-controlled, dose-finding study to investigate the safety and efficacy of Lybridos in the domestic setting in healthy female subjects with hypoactive sexual desire disorder and maladaptive…
- Trial name
- NCT02101203
- Testing
- 0.5 mgTestosterone + 10 mg Buspirone
- Where
- 10 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Emotional Brain NY Inc.
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in naturally menopausal women who are taking estrogen or estrogen/progestin therapy.
- Trial name
- NCT00338312
- Testing
- Testosterone Transdermal System
- Where
- United States
- Volunteers
- 610 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder (HSDD)
Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire
This is study of the efficacy, safety and pharmacokinetics of BP101 compared to placebo in patients with a decrease or loss of sexual desire.
- Trial name
- NCT03080298
- Testing
- BP101
- Where
- 12 sites in Russia
- Volunteers
- 119 people
- Sponsor
- Ivix LLX
Hypoactive Sexual Desire Disorder
Effects of Flibanserin on the Pre- and Post-menopausal Female Brain
The purpose of the present study is to understand the neurobiological mechanisms of action underlying sexual desire building on prior work Dr. Stephanie Cacioppo has done in which desire was not manipulated.
- Trial name
- NCT02770768
- Testing
- Flibanserin
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Chicago